Poly Medicure Ltd

- There is no explicit mention of any current or upcoming fundraising through debt or equity in the provided pages. - The company highlights a strong cash/liquidity position of INR 840 crores as of the recent quarter, supporting its organic and inorganic growth strategy. - The focus is on using this cash position to back ambitious growth, including acquisitions and technology investments. - The management emphasizes prudence in guidance and plans to update investors in forthcoming calls once more clarity on business plans is achieved. - No specific plans for raising additional capital via debt or equity are discussed or indicated in the excerpts.

- Capex of INR 234 crores done in the first 9 months of the current financial year. - Funds deployed to set up new factories in Mitrol and Haridwar, as well as to expand capacity at existing plants. - Additional land bought at YEIDA Medical Devices Park near Noida in Jewar for a new facility. - New facility expected to be operational within 18 to 24 months after local approvals. - Three new plants planned to be fully operational within the next 18 to 24 months. - Continued investments support ambitious growth strategy including organic and inorganic expansion. - Focus on technology acquisitions complementing verticals like critical care, cardiology, and orthopedics. - R&D center expansion and operational excellence improvements underway to support acquisitions.

- Poly Medicure expects overall consolidated revenue growth of around 20% or more for FY '27. - Domestic business is projected to grow between 20% to 25%, driven by a stronger private market presence. - International business growth is expected in the 12% to 15% range, including contributions from recent acquisitions. - New acquisitions and subsidiaries, such as Plan1 Health (oncology business), are contributing significant growth (e.g., 30-35% year-on-year for Plan1 Health). - The company aims to regain a 20% constant growth rate after a challenging year. - Growth strategies include expanding clinical teams internationally to better penetrate 25-30 major markets. - Introduction of 10-15 new CE Mark products for international markets and 15 new EU MDR-approved products for Europe expected to enhance sales. - Investment in domestic clinical training and new contracts (e.g., NHS UK) anticipated to support both domestic and international growth.

- For FY '26, operating profit is expected to be similar to previous year (~INR450 crores). - FY '27 revenue growth guidance is around 20% overall. - Domestic business expected to grow 20-25%. - International business (including acquisitions) expected growth of 12-15%. - Profit pool (operating profit) for FY '27 likely to grow roughly in line with turnover (~20% growth). - Margins to remain steady; standalone domestic and international businesses have superior margins compared to acquisitions. - Integration and product pipeline (CE Mark products) expected to support growth. - Management to provide more precise guidance after Q4. - EPS growth expected to be consistent with the operating profit growth, barring exceptional items. In summary, earnings and operating profits are expected to grow about 20% in FY '27, with consistent margins and better visibility post Q4.

The provided pages from the Poly Medicure Limited document do not explicitly mention the current or expected order book or pending orders in specific terms. However, relevant points that indicate future business visibility and growth prospects include: - New contracts won in larger European markets are expected to help recover lost revenue. - NHS contracts in the U.K. are expected to commence, aiding growth in Europe. - Pipeline of 10 to 15 new CE Marked products to support expansion in international markets, particularly Europe. - Anticipated growth in domestic business with 25% expected, and international growth guidance of 12-15% for FY '27. - Acquisitions (Citieffe and PendraCare) contribute to growth and product approvals in the U.S. - Plans to finalize detailed business plans and exact numbers by the end of Q4 for FY '27. - Clinical teams established internationally to drive product adoption and increase market share. No explicit numeric order book or pending order values are disclosed in the discussed transcript.